Haemonetics HAE Plasma — Restructuring related costs
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept hae:RestructuringRelatedCosts.
The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Haemonetics's plasma — restructuring related costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Haemonetics's plasma — restructuring related costs?
- Haemonetics (HAE) reported plasma — restructuring related costs of $0 in Q1 2026.
- How has Haemonetics's plasma — restructuring related costs changed year-over-year?
- Haemonetics's plasma — restructuring related costs decreased by 100.0% year-over-year, from $18K to $0.
- What is the long-term trend for Haemonetics's plasma — restructuring related costs?
- Over 4 years (2022 to 2026), Haemonetics's plasma — restructuring related costs has grown at a -81.6% compound annual growth rate (CAGR), from $7.91M to $9K.
- What does plasma — restructuring related costs mean?
- Captures expenses directly associated with organizational restructuring, such as severance, facility closures, or process realignments within the plasma segment. Monitoring these costs is essential for understanding the impact of strategic transformations on short-term profitability. High levels of these costs indicate active efforts to optimize the segment's cost structure.